Page 34 - MI-2-4

Microbes & Immunity Infectious agents and autoimmune diseases

hypothesis and autoimmune diseases: A narrative review doi: 10.1016/B978-0-12-800763-1.00015-4
of clinical evidences and mechanisms. Autoimmun Rev. 65. Zhu YX, Li ZY, Yu ZL, et al. The underlying mechanism and
2021;20(7):102845.
therapeutic potential of IFNs in viral-associated cancers. Life
doi: 10.1016/j.autrev.2021.102845 Sci. 2025;361:123301.
59. Pruett SB. Stress and the immune system. Pathophysiology. doi: 10.1016/j.lfs.2024.123301
2003;9(3):133-153.
66. Xiao X, Chang C. Diagnosis and classification of
doi: 10.1016/S0928-4680(03)00003-8 drug-induced autoimmunity (DIA). J Autoimmun.
2014;48-49:66-72.
60. Jacobs R, Pawlak CR, Mikeska E, et al. Systemic lupus
erythematosus and rheumatoid arthritis patients differ doi: 10.1016/j.jaut.2014.01.005
from healthy controls in their cytokine pattern after stress 67. Graus F, Dalmau J. Paraneoplastic neurological syndromes
exposure. Rheumatology. 2001;40(8):868-875.
in the era of immune-checkpoint inhibitors. Nat Rev Clin
doi: 10.1093/rheumatology/40.8.868 Oncol. 2019;16:535-548.
61. Mitsonis CI, Potagas C, Zervas I, Sfagos K. The effects of doi: 10.1038/s41571-019-0194-4
stressful life events on the course of multiple sclerosis: 68. Möhn N, Beutel G, Gutzmer R, et al. Neurological
A review. Int J Neurosci. 2009;119(3):315-335.
immune related adverse events associated with nivolumab,
doi: 10.1080/00207450802480192 ipilimumab, and pembrolizumab therapy-review of the
literature and future outlook. J Clin Med. 2019;8(11):1777.
62. Song H, Fang F, Tomasson G, et al. Association of stress-
related disorders with subsequent autoimmune disease. doi: 10.3390/jcm8111777
JAMA. 2018;319(23):2388-2400.
69. Cano-Cruz LG, Barrera-Vargas A, Mateos-Soria A, Soto-
doi: 10.1001/jama.2018.7028 Perez-de-Celis E, Merayo-Chalico J. Rheumatological
adverse events of cancer therapy with immune checkpoint
63. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action
in multiple sclerosis. Neurology. 2010;74(1 Suppl):S17-S24. inhibitors. Arch Med Res. 2022;53(2):113-121.
doi: 10.1016/j.arcmed.2021.09.004
doi: 10.1212/WNL.0b013e3181c97d99
70. Zhai Y, Moosavi R, Chen M. Immune checkpoints, a novel
64. Hojati Z, Kay M, Dehghanian F. Mechanism of action
of interferon beta in treatment of multiple sclerosis. In: class of therapeutic targets for autoimmune diseases. Front
Minagar A, editor. Multiple Sclerosis. Ch. 15. United States: Immunol. 2021;12:645699.
Academic Press; 2016. p. 365-392. doi: 10.3389/fimmu.2021.645699

Volume 2 Issue 4 (2025) 26 doi: 10.36922/MI025100017